A prospective, randomized, two-arm, single-blind, parallel, active-controlled, multicenter, non-inferiority clinical study to evaluate the immunogenicity and safety of Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Cadila Healthcare Limited compared to Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Panacea Biotec Limited in healthy infants - None

Trial Profile

A prospective, randomized, two-arm, single-blind, parallel, active-controlled, multicenter, non-inferiority clinical study to evaluate the immunogenicity and safety of Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Cadila Healthcare Limited compared to Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Panacea Biotec Limited in healthy infants - None

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Hib-DTP vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Pertussis; Tetanus
  • Focus Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top